NASDAQ:BGNE
BeiGene Ltd Stock News
$172.85
+1.82 (+1.06%)
At Close: May 17, 2024
Why BeiGene (BGNE) Might Surprise This Earnings Season
10:32am, Wednesday, 03'rd Aug 2022
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
BeiGene, Ltd. (BGNE) Soars 15.5%: Is Further Upside Left in the Stock?
09:17am, Wednesday, 22'nd Jun 2022
BeiGene, Ltd. (BGNE) witnessed a jump in share price last session on above-average trading volume.
Why Shares of BeiGene Popped Today
03:10pm, Tuesday, 21'st Jun 2022
Regulators in China agreed to start the review process for one of its medicines.
Why Earnings Season Could Be Great for BeiGene (BGNE)
03:03pm, Wednesday, 04'th May 2022
BeiGene (BGNE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week
08:17am, Wednesday, 04'th May 2022
Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.
Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial
09:47am, Wednesday, 27'th Apr 2022
Novartis AG (NYSE: NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Dat
BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study
12:02pm, Tuesday, 12'th Apr 2022
BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.
BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia Study
02:50pm, Monday, 11'th Apr 2022
BeiGene Ltd (NASDAQ: BGNE) has announced results from the Phase 3 ALPINE trial of Brukinsa (zanubrutinib) in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymph
BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors at the AACR Annual Meeting 2022
07:00am, Friday, 08'th Apr 2022
CAMBRIDGE, Mass. & BEIJING & BASEL, Switzerland--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing
Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework
02:31pm, Friday, 01'st Apr 2022
According to a Bloomberg report, U.S. regulators could reportedly have full access to auditing reports from most of the 200-plus China-based companies listed in New York in mid-2022. In the drafting
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
11:31pm, Tuesday, 29'th Mar 2022
Tekla Healthcare Investors: A Dividend Paymaster That Can Compensate For Poor Price Performance
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
06:25am, Monday, 28'th Mar 2022
Weibo Corp (WB), on Wednesday, joined previously identified Chinese stocks that may be delisted from U.S. exchanges. More could follow and Alibaba (BABA) could be in SEC crosshairs too.
Dow Jones Newswires: SEC-targeted Chinese companies slump; Yum China warns of 2024 delisting risk
11:26am, Saturday, 26'th Mar 2022
Shares of Chinese companies flagged for possible delisting in the U.S. slid in Hong Kong and Shanghai trading Friday, a move that analysts said highlighted geopolitical tensions but would have little
Which Chinese Stocks Could Get Delisted? 6 Companies to Watch.
02:53pm, Friday, 25'th Mar 2022
Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way. The post Which Chinese Stocks Could Get Delisted?
BeiGene, Ltd. (BGNE) Soars 25.1%: Is Further Upside Left in the Stock?
06:47am, Thursday, 17'th Mar 2022
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average.
